These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31658514)
1. [Developing process of guide on methodological standards in pharmacoepidemiology (T/CPHARMA 002-2019)]. Xu Y; Ding CY; Zhuo L; Zhan SY Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Oct; 40(10):1186-1190. PubMed ID: 31658514 [TBL] [Abstract][Full Text] [Related]
2. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology]. Tian F; Liao X; Xie YM Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310 [TBL] [Abstract][Full Text] [Related]
3. [Guide on methodological standards in pharmacoepidemiology (T/CPHARMA 002-2019)]. Pharmacoepidemiology Professional Committee of Chinese Pharmaceutical Association Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Oct; 40(10):1180-1185. PubMed ID: 31658513 [No Abstract] [Full Text] [Related]
4. Guidelines for good pharmacoepidemiology practice (GPP). Public Policy Committee, International Society of Pharmacoepidemiology Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):2-10. PubMed ID: 26537534 [No Abstract] [Full Text] [Related]
5. [Pharmacoepidemiolgy: regulatory basis, methodological approaches and scope]. Ahid S; Belaguide K; Cherrah Y East Mediterr Health J; 2012 Jan; 18(1):85-93. PubMed ID: 22360016 [TBL] [Abstract][Full Text] [Related]
6. Quality of reporting of drug exposure in pharmacoepidemiological studies. Hempenius M; Luijken K; de Boer A; Klungel O; Groenwold R; Gardarsdottir H Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1141-1150. PubMed ID: 32394589 [TBL] [Abstract][Full Text] [Related]
7. [Future Perspective of Pharmacoepidemiology in the "Big Data Era" and the Growth of Information Sources]. Macías Saint-Gerons D; de la Fuente Honrubia C; de Andrés Trelles F; Catalá-López F Rev Esp Salud Publica; 2016 Dec; 90():e1-e7. PubMed ID: 27905352 [TBL] [Abstract][Full Text] [Related]
8. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations. Consiglio GP; Burden AM; Maclure M; McCarthy L; Cadarette SM Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1146-53. PubMed ID: 24030723 [TBL] [Abstract][Full Text] [Related]
9. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Conte C; Vaysse C; Bosco P; Noize P; Fourrier-Reglat A; Despas F; Lapeyre-Mestre M Therapie; 2019 Apr; 74(2):279-288. PubMed ID: 30824175 [TBL] [Abstract][Full Text] [Related]
10. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA BMC Res Notes; 2015 Nov; 8():634. PubMed ID: 26526064 [TBL] [Abstract][Full Text] [Related]
11. Study designs in paediatric pharmacoepidemiology. Verhamme K; Sturkenboom M Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():67-74. PubMed ID: 21107830 [TBL] [Abstract][Full Text] [Related]
12. Medication safety research by observational study design. Lao KS; Chui CS; Man KK; Lau WC; Chan EW; Wong IC Int J Clin Pharm; 2016 Jun; 38(3):676-84. PubMed ID: 27003827 [TBL] [Abstract][Full Text] [Related]
13. Ethical issues in pharmacoepidemiological research in Belgium. Verstraete AG; Vander Stichele RH; Deliens LH Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):595-9. PubMed ID: 11980246 [TBL] [Abstract][Full Text] [Related]
14. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT Stat Med; 1998 Aug 15-30; 17(15-16):1851-8; discussion 1859-62. PubMed ID: 9749452 [TBL] [Abstract][Full Text] [Related]
15. Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies. Willame C; Baril L; van den Bosch J; Ferreira GL; Williams R; Rosillon D; Cohet C Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1397-1406. PubMed ID: 27601179 [TBL] [Abstract][Full Text] [Related]
16. An analysis of the exclusion criteria used in observational pharmacoepidemiological studies. Perrio M; Waller PC; Shakir SA Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):329-36. PubMed ID: 16741894 [TBL] [Abstract][Full Text] [Related]
17. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Wang SV; Kulldorff M; Glynn RJ; Gagne JJ; Pottegård A; Rothman KJ; Schneeweiss S; Walker AM Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):567-569. PubMed ID: 29701279 [No Abstract] [Full Text] [Related]